Axon Enterprise, Inc. (NASDAQ:AXON) Position Increased by Realta Investment Advisors

Realta Investment Advisors increased its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 23.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,844 shares of the biotechnology company’s stock after acquiring an additional 347 shares during the quarter. Realta Investment Advisors’ holdings in Axon Enterprise were worth $808,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Farther Finance Advisors LLC grew its position in Axon Enterprise by 19.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 875 shares of the biotechnology company’s stock worth $350,000 after purchasing an additional 142 shares in the last quarter. Gladstone Institutional Advisory LLC raised its position in Axon Enterprise by 1.6% during the third quarter. Gladstone Institutional Advisory LLC now owns 1,641 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 26 shares during the period. Interchange Capital Partners LLC raised its position in Axon Enterprise by 3.3% during the third quarter. Interchange Capital Partners LLC now owns 1,285 shares of the biotechnology company’s stock valued at $513,000 after buying an additional 41 shares during the period. Stephens Inc. AR raised its position in Axon Enterprise by 4.9% during the third quarter. Stephens Inc. AR now owns 3,886 shares of the biotechnology company’s stock valued at $1,553,000 after buying an additional 181 shares during the period. Finally, Oak Ridge Investments LLC lifted its stake in Axon Enterprise by 16.1% in the 3rd quarter. Oak Ridge Investments LLC now owns 14,371 shares of the biotechnology company’s stock worth $5,743,000 after acquiring an additional 1,991 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on AXON shares. JMP Securities upped their target price on Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a report on Thursday. Needham & Company LLC lifted their target price on shares of Axon Enterprise from $400.00 to $525.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Robert W. Baird boosted their price target on shares of Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Jefferies Financial Group started coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $385.00 price target on the stock. Finally, Northland Securities upped their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $388.23.

Insiders Place Their Bets

In other news, Director Matthew R. Mcbrady sold 2,000 shares of the stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $364.66, for a total value of $729,320.00. Following the completion of the sale, the director now directly owns 4,892 shares of the company’s stock, valued at approximately $1,783,916.72. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Axon Enterprise news, Director Julie A. Cullivan sold 900 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $353.53, for a total value of $318,177.00. Following the completion of the transaction, the director now owns 3,653 shares of the company’s stock, valued at $1,291,445.09. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Matthew R. Mcbrady sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $364.66, for a total value of $729,320.00. Following the completion of the sale, the director now owns 4,892 shares of the company’s stock, valued at $1,783,916.72. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 371,172 shares of company stock valued at $137,000,162 in the last three months. Company insiders own 6.10% of the company’s stock.

Axon Enterprise Stock Performance

Shares of NASDAQ AXON traded up $2.34 during trading hours on Friday, hitting $425.84. 600,627 shares of the stock were exchanged, compared to its average volume of 476,180. Axon Enterprise, Inc. has a one year low of $209.02 and a one year high of $455.17. The company’s 50 day moving average is $402.34 and its 200 day moving average is $340.57. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The firm has a market capitalization of $32.18 billion, a P/E ratio of 112.36, a P/E/G ratio of 10.78 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. During the same period in the prior year, the company earned $0.80 earnings per share. The business’s quarterly revenue was up 34.5% compared to the same quarter last year. On average, research analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.